Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1372951 | 1.00 | TSHR (0.43) | TSHRKMT2AKDM4EMEN1FABP7 | |
| SCHEMBL29401030 | 0.89 | FABP7 (0.46) | TSHRKMT2AKDM4EMEN1FABP7 | |
| SCHEMBL29516735 | 0.89 | FABP7 (0.46) | TSHRKMT2AKDM4EMEN1FABP7 | |
| SCHEMBL118231 | 0.89 | FABP7 (0.46) | TSHRKMT2AKDM4EMEN1FABP7 | |
| SCHEMBL4362743 | 0.89 | FABP7 (0.46) | TSHRKMT2AKDM4EMEN1FABP7 | |
| SCHEMBL799721 | 0.89 | FABP7 (0.46) | TSHRKMT2AKDM4EMEN1FABP7 | |
| SCHEMBL29710361 | 0.89 | FABP7 (0.46) | TSHRKMT2AKDM4EMEN1FABP7 | |
| SCHEMBL4353637 | 0.86 | TSHR (0.41) | TSHRKMT2AKDM4EMEN1FABP7 | |
| SCHEMBL1537138 | 0.86 | TSHR (0.41) | TSHRKMT2AKDM4EMEN1FABP7 | |
| SCHEMBL874549 | 0.85 | SMN1; SMN2 (0.48) | KMT2AKDM4EMEN1FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180291029-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2018-10-11 | — | — | US | disclosed |
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| EP-3031324-A2 | TRICYCLIC KINASE INHIBITORS | AbbVie Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| US-9365579-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365579-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365579-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2299821-B1 | TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2299821-B1 | TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150210708-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210708-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210708-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-8962629-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962629-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962629-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20090312338-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312338-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312338-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180291029-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | TSHR 3417/4885KMT2A 3801/4885KDM4E 4050/4885 |
| US-20090312338-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | TSHR 3417/4885KMT2A 3801/4885KDM4E 4050/4885 |
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | TSHR 3417/4885KMT2A 3801/4885KDM4E 4050/4885 |
| US-20150210708-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | TSHR 3417/4885KMT2A 3801/4885KDM4E 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.